Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 15/20 | 0.78 |
| ▸ | MMP2 | P08253 | 7/20 | 0.78 |
| ▸ | MMP9 | P14780 | 7/20 | 0.78 |
| ▸ | MMP3 | P08254 | 7/20 | 0.78 |
| ▸ | MMP1 | P03956 | 6/20 | 0.78 |
| ▸ | MMP7 | P09237 | 4/20 | 0.78 |
| ▸ | MMP8 | P22894 | 4/20 | 0.78 |
| ▸ | MMP13 | P45452 | 4/20 | 0.78 |
| ▸ | MMP14 | P50281 | 4/20 | 0.78 |
| ▸ | ADAM10 | O14672 | 4/20 | 0.78 |
| ▸ | MMP15 | P51511 | 1/20 | 0.51 |
| ▸ | MMP16 | P51512 | 1/20 | 0.51 |
| ▸ | ADAM33 | Q9BZ11 | 1/20 | 0.51 |
| ▸ | ADAM9 | Q13443 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1021287 | 0.88 | ADAM17 (1.00) | ADAM17MMP2MMP9MMP3MMP1 | |
| SCHEMBL6350415 | 0.88 | ADAM17 (1.00) | ADAM17MMP2MMP9MMP3MMP1 | |
| SCHEMBL6350418 | 0.88 | ADAM17 (1.00) | ADAM17MMP2MMP9MMP3MMP1 | |
| SCHEMBL29732231 | 0.88 | ADAM17 (1.00) | ADAM17MMP2MMP9MMP3MMP1 | |
| SCHEMBL6508150 | 0.81 | ADAM17 (0.78) | ADAM17MMP2MMP9MMP3MMP1 | |
| SCHEMBL6681213 | 0.80 | ADAM17 (0.86) | ADAM17MMP2MMP9MMP3MMP1 | |
| SCHEMBL6681788 | 0.79 | ADAM17 (0.84) | ADAM17MMP2MMP9MMP3MMP1 | |
| SCHEMBL6685255 | 0.79 | ADAM17 (0.84) | ADAM17MMP2MMP9MMP3MMP1 | |
| SCHEMBL8282217 | 0.78 | ADAM17 (1.00) | ADAM17MMP2MMP9MMP3MMP1 | |
| SCHEMBL4193352 | 0.78 | ADAM17 (1.00) | ADAM17MMP2MMP9MMP3MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11123286-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20200230051-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY, INC. | 2020-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11123286-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | ADAM17 2372/4885MMP2 1635/4885MMP9 1690/4885 |
| US-20200230051-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | ADAM17 2372/4885MMP2 1635/4885MMP9 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.